Table 3
Responders (≥ 50% Individual Improvement)
| Observed unadjusted % of responders | Slope (95% CI) | Adjusted difference in percentage of responders (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| SMT 0 | SMT 6 | SMT 12 | SMT 18 | per 6 SMT sessions | SMT 0 vs SMT 6 | SMT 0 vs SMT 12 | SMT 0 vs SMT 18 | |
| Pain intensity | ||||||||
| 6 wk | 32.6 | 28.3 | 46.4 | 45.0 | 5.5 (1.3, 9.8)* | −3.7 (−16.2, 8.8) | 13.7 (0.6, 26.9) | 13.0 (−0.4, 26.5) |
| 12 wk | 28.4 | 38.4 | 49.5 | 37.0 | 3.8 (−0.5, 8.1) | 10.0 (−3.2, 23.1) | 21.1 (7.7, 34.6)* | 8.9 (−4.2, 21.9) |
| 18 wk | 32.6 | 37.4 | 43.3 | 47.0 | 4.8 (0.5, 9.2) | 4.3 (−9.1, 17.6) | 10.3 (−3.3, 23.9) | 14.2 (0.5, 27.9) |
| 24 wk | 36.8 | 40.4 | 40.2 | 42.0 | 1.4 (−2.9, 5.7) | 3.7 (−10.0, 17.4) | 3.2 (−10.5, 16.9) | 4.9 (−8.7, 18.4) |
| 39 wk | 32.6 | 41.4 | 45.4 | 47.0 | 4.8 (0.5, 9.1) | 9.0 (−4.5, 22.5) | 13.0 (−0.7, 26.6) | 14.6 (1.1, 28.1) |
| 52 wk | 37.9 | 47.5 | 41.2 | 48.0 | 2.5 (−1.9, 6.9) | 10.2 (−3.5, 23.9) | 3.9 (−9.8, 17.6) | 10.6 (−3.2, 24.4) |
| Functional disability | ||||||||
| 6 wk | 49.5 | 47.5 | 50.5 | 42.0 | −0.1 (−0.5, 0.3) | −2.0 (−16.1, 12.0) | 0.9 (−13.2, 15.1) | −7.5 (−21.4, 6.5) |
| 12 wk | 43.2 | 49.5 | 59.8 | 55.0 | 4.4 (0.0, 8.8) | 6.2 (−7.7, 20.0) | 16.8 (2.9, 30.6)* | 11.5 (−2.4, 25.4) |
| 18 wk | 50.5 | 54.5 | 63.9 | 56.0 | 2.5 (−1.9, 6.9) | 3.7 (−10.4, 17.9) | 13.5 (−0.3, 27.2) | 3.5 (−8.8, 19.3) |
| 24 wk | 49.5 | 51.5 | 59.8 | 54.0 | 2.2 (−2.2, 6.6) | 2.5 (−11.5, 16.5) | 10.4 (−3.4, 24.3) | 4.8 (−9.1, 18.6) |
| 39 wk | 51.6 | 56.6 | 61.9 | 54.0 | 1.2 (−3.2, 5.6) | 4.9 (−9.0, 18.8) | 10.4 (−3.4, 24.2) | 2.5 (−11.5, 16.4) |
| 52 wk | 58.9 | 57.6 | 57.7 | 62.0 | 0.8 (−3.5, 5.2) | −1.1 (−14.8, 12.6) | −1.4 (−15.4, 12.6) | 2.7 (−11.0, 16.5) |
Unadjusted group percentages are from original data without imputation; slopes and group differences in responders are computed from imputed data adjusted for the baseline covariates. Positive signs of slopes and mean differences were computed to favor higher doses of SMT.
*P < .025